Literature DB >> 25523435

National Lipid Association Annual Summary of Clinical Lipidology 2015.

Harold E Bays1, Peter H Jones2, W Virgil Brown3, Terry A Jacobson4.   

Abstract

The National Lipid Association (NLA) Annual Summary of Clinical Lipidology 2015 is a summary of principles important to the patient-centered evaluation, management, and care of patients with dyslipidemia. This summary is intended to be a "living document," with future annual updates based on emerging science, clinical considerations, and new NLA Position and Consensus Statements. The goal is to provide clinicians an ongoing resource that translates the latest advances in medical science toward the evaluation and treatment of patients with dyslipidemia. The 2015 NLA Annual Summary of Clinical Lipidology was founded on the principles of evidence-based medicine and is generally consistent with established national and international lipid guidelines. Topics include a general discussion of the 2014 NLA Recommendations for Patient-Centered Management of Dyslipidemia, genetics, secondary causes of dyslipidemia, biomarkers and "advanced lipid testing," medical nutrition, physical activity, obesity, pharmacotherapy, statin safety, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia in children and adolescence, dyslipidemia in older individuals, race/ethnicity, and women, health information technology and electronic medical records, as well as investigational lipid-altering drugs in development.
Copyright © 2014 National Lipid Association. All rights reserved.

Entities:  

Keywords:  Annual Summary; Cholesterol; Clinical Lipidology; Dyslipidemia; Guidelines; National Lipid Association; Recommendations

Mesh:

Year:  2014        PMID: 25523435     DOI: 10.1016/j.jacl.2014.10.002

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  23 in total

1.  Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

Authors:  Harold Bays; Daniel Gaudet; Robert Weiss; Juan Lima Ruiz; Gerald F Watts; Ioanna Gouni-Berthold; Jennifer Robinson; Jian Zhao; Corinne Hanotin; Stephen Donahue
Journal:  J Clin Endocrinol Metab       Date:  2015-06-01       Impact factor: 5.958

2.  Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals.

Authors:  Danit Ariel; Sun H Kim; Alice Liu; Fahim Abbasi; Cindy A Lamendola; Kaylene Grove; Vanessa Tomasso; Gerald M Reaven
Journal:  J Clin Lipidol       Date:  2015-06-18       Impact factor: 4.766

Review 3.  How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention.

Authors:  Lane B Benes; Daniel J Brandt; Eric J Brandt; Michael H Davidson
Journal:  Curr Cardiol Rep       Date:  2018-10-17       Impact factor: 2.931

Review 4.  [Statin intolerance and statin-associated muscular pain].

Authors:  Paulina Elena Stürzebecher; Friederike Schumann; Ursula Kassner; Ulrich Laufs
Journal:  Herz       Date:  2022-04-22       Impact factor: 1.740

5.  Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort.

Authors:  Akinyemi Oni-Orisan; Thomas J Hoffmann; Dilrini Ranatunga; Marisa W Medina; Eric Jorgenson; Catherine Schaefer; Ronald M Krauss; Carlos Iribarren; Neil Risch
Journal:  Circ Genom Precis Med       Date:  2018-09

Review 6.  Statin use in prediabetic patients: rationale and results to date.

Authors:  Anastazia Kei; Evangelos C Rizos; Moses Elisaf
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

Review 7.  Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions.

Authors:  Ozlem Bilen; Ayeesha Kamal; Salim S Virani
Journal:  World J Cardiol       Date:  2016-03-26

8.  Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.

Authors:  Arpita Basu; Alicia J Jenkins; Ying Zhang; Julie A Stoner; Richard L Klein; Maria F Lopes-Virella; W Timothy Garvey; Timothy J Lyons
Journal:  Atherosclerosis       Date:  2015-10-31       Impact factor: 5.162

9.  Gualou Xiebai Banxia decoction ameliorates Poloxamer 407-induced hyperlipidemia.

Authors:  Mingzhu Luo; Rong Fan; Xiaoming Wang; Junyu Lu; Ping Li; Wenbin Chu; Yonghe Hu; Xuewei Chen
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.976

10.  Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk.

Authors:  Ruben G W Quek; Kathleen M Fox; Li Wang; Lu Li; Shravanthi R Gandra; Nathan D Wong
Journal:  BMJ Open Diabetes Res Care       Date:  2015-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.